Hypersensitivity: Clinical Trials

162 trials for Hypersensitivity, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

162 terminated. 162 Phase 2, 26 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2162Terminated 162
Phase 126Terminated 26
Phase 35Terminated 5

Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity

Trials (filtered) newest first · largest first

All 162 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
Dupilumab, Placebo, IBI356 - Atopic Dermatitis
Phase 2TerminatedInnovent Biologics (Suzhou) Co. Ltd.182025-12-312026-10-27
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Dupilumab, JNJ-95475939, Placebo - Dermatitis, Atopic
Phase 2TerminatedJanssen Research & Development, LLC2562025-02-262026-07-31
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment - Chronic Urticaria, Idiopathic, Hidradenitis
Phase 2TerminatedInflaRx GmbH732025-01-022026-02-03
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
Briquilimab - Urticaria Chronic
Phase 2TerminatedJasper Therapeutics, Inc.672024-11-262026-08-06
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
GSK1070806, Placebo - Dermatitis, Atopic
Phase 2TerminatedGlaxoSmithKline792024-06-052026-06-16
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
Rocatinlimab, Placebo - Asthma
Phase 2TerminatedAmgen3172024-05-242026-08-11
A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
Briquilimab - Chronic Inducible Urticaria
Phase 1 / Phase 2TerminatedJasper Therapeutics, Inc.272024-03-182025-10-08
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy
Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo - Uncontrolled Asthma
Phase 2TerminatedChiesi Farmaceutici S.p.A.5172023-11-262025-12-18
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
GSK1070806, Placebo - Dermatitis, Atopic
Phase 2TerminatedGlaxoSmithKline1612023-11-162026-06-03
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
SAR444656 (KT-474), Placebo - Atopic Dermatitis
Phase 2TerminatedSanofi702023-11-092026-11-03
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
Oral EP262, Placebo - Chronic Spontaneous Urticaria
Phase 2TerminatedEscient Pharmaceuticals, Inc1132023-09-252025-12-19
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Amlitelimab, Placebo - Asthma
Phase 2TerminatedSanofi3352023-09-052026-10-02
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Phase 1 / Phase 2TerminatedInmagene LLC132023-08-092025-11-06
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
RPT193, Placebo - Asthma
Phase 2TerminatedRAPT Therapeutics, Inc., a member of the GSK plc group of companies382023-07-052026-03-23
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
LY3454738, Placebo - Atopic Dermatitis
Phase 2TerminatedEli Lilly and Company2342023-06-212025-12-02
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
Itraconazole Powder, Placebo - ABPA
Phase 2TerminatedPulmatrix Inc.82023-02-012024-04-02
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified
Phase 2 / Phase 3TerminatedPfizer582023-01-182025-05-08
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
BMX-010, Placebo - Atopic Dermatitis
Phase 2TerminatedBioMimetix JV, LLC1032023-01-082024-04-18
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
Lirentelimab (AK002), Placebo - Chronic Spontaneous Urticaria
Phase 2TerminatedAllakos Inc.1272022-10-262024-09-27
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Namilumab, Placebo - Sarcoidosis, Pulmonary
Phase 2TerminatedKinevant Sciences GmbH1072022-08-312025-09-12

Showing 20 of 162. Sign in to see all of them.

Narrower conditions

Asthma (58)  ·  Dermatitis, Atopic (45)  ·  Eczema (13)  ·  Urticaria (12)  ·  Chronic Urticaria (9)  ·  Dermatitis (8)  ·  Food Hypersensitivity (7)  ·  Pruritus (7)  ·  Sarcoidosis (7)  ·  Immune System Diseases (6)  ·  Rhinitis, Allergic (5)  ·  Skin Diseases (5)  ·  Eosinophilic Esophagitis (4)  ·  Lymphoma, Follicular (4)

Broader conditions

Immune System Diseases (156)  ·  Hypersensitivity, Immediate (142)  ·  Respiratory Tract Diseases (71)  ·  Skin and Connective Tissue Diseases (68)  ·  Lung Diseases (67)  ·  Respiratory Hypersensitivity (65)  ·  Skin Diseases (63)  ·  Bronchial Diseases (58)  ·  Lung Diseases, Obstructive (58)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (51)  ·  Genetic Diseases, Inborn (51)  ·  Skin Diseases, Genetic (48)  ·  Skin Diseases, Eczematous (44)  ·  Dermatitis (39)

Interventions

dupilumab (5)  ·  Fluticasone (3)  ·  AK002 (2)  ·  Azithromycin (2)  ·  Bosentan (2)  ·  Epinephrine (2)  ·  GSK1070806 (2)  ·  Omalizumab (2)  ·  Rituximab (2)  ·  Therapeutics (2)  ·  benralizumab (2)  ·  bermekimab (2)  ·  enokizumab (2)  ·  itepekimab (2)  ·  ligelizumab (2)

Sponsors

Novartis Pharmaceuticals (11)  ·  GlaxoSmithKline (5)  ·  AstraZeneca (4)  ·  Boehringer Ingelheim (4)  ·  Johns Hopkins University (4)  ·  Amgen (3)  ·  Eli Lilly and Company (3)  ·  Janssen Research & Development, LLC (3)  ·  MedImmune LLC (3)  ·  Pfizer (3)  ·  Regeneron Pharmaceuticals (3)  ·  University of Chicago (3)  ·  Allakos Inc. (2)  ·  Amphastar Pharmaceuticals, Inc. (2)  ·  DermBiont, Inc. (2)

Countries

United States (109)  ·  Germany (44)  ·  Poland (40)  ·  Canada (37)  ·  United Kingdom (26)  ·  France (19)  ·  Spain (19)  ·  Czechia (18)  ·  Japan (18)  ·  South Korea (16)  ·  Hungary (15)  ·  Australia (14)  ·  Bulgaria (14)  ·  Argentina (12)  ·  Belgium (11)

Top investigators

Chin Lee, MD, MPH (2)  ·  Joseph Parker, M.D. (2)  ·  Alessio Fasano, M. D. (1)  ·  Alex Zvulunov, Prof (1)

Results publications

PMID 39077906, PMID 12384926, PMID 15201414, PMID 15334472, PMID 16899778, PMID 17478385, PMID 18645136, PMID 21356110, PMID 21945511, PMID 22294344, PMID 23234805, PMID 23949578, PMID 24751453, PMID 25223501, PMID 27143789, PMID 28118536, PMID 32150492, PMID 32840597, PMID 33006765, PMID 33032168, PMID 33293212, PMID 33314326, PMID 33397449, PMID 33831327, PMID 34048641, PMID 34326185, PMID 36735745, PMID 37951310, PMID 37965347, PMID 38814736, PMID 39393433, PMID 40766832, PMID 41200192, PMID 41819539, PMID 41865746

NIH funding

2018 (10), 2023 (5), 2017 (2), 2019 (2), 2008 (1), 2009 (1), 2014 (1), P01AT002647 (1), R21AT004089 (1), U01AI140498 (1), U01HL119952 (1), ZIAAR041138-08 (1)